gamma-aminobutyric acid has been researched along with Adenoma Sebaceum in 12 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Adenoma Sebaceum: Facial ANGIOFIBROMA in tuberous sclerosis
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vigabatrin has been shown to be efficient in infants with infantile spasms and tuberous sclerosis, in open studies." | 9.08 | Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 1997) |
| "The purpose of this report is to review the efficacy and safety of vigabatrin in the treatment of infantile spasms in infants suffering from tuberous sclerosis complex." | 8.80 | Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. ( Hancock, E; Osborne, JP, 1999) |
| " While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 7.79 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| "The purpose of this study was to estimate the gamma-aminobutyric acid (GABA) and glutamate plus glutamine (Glx) concentrations in the cortical tubers of patients with tuberous sclerosis complex (TSC) using the MEGA-editing J-difference method and a stimulated echo-acquisition mode with a short echo time, and to determine which abnormality was more dominant between GABA and Glx in patients with TSC with epilepsy." | 7.75 | High gamma-aminobutyric acid level in cortical tubers in epileptic infants with tuberous sclerosis complex measured with the MEGA-editing J-difference method and a three-Tesla clinical MRI Instrument. ( Harada, M; Kubo, H; Matsuda, T; Mori, K; Nishitani, H; Nose, A; Taki, MM, 2009) |
| "We present the results of treatment with vigabatrin in the polytherapy of resistant infantile epilepsy." | 7.69 | [Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients]. ( Hernández-Laín, A; López-Valdés, E; Mateos, F; Porta, J; Simón, R, 1996) |
| "Vigabatrin has been shown to be efficient in infants with infantile spasms and tuberous sclerosis, in open studies." | 6.68 | Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 1997) |
| "Of the 313 patients without tuberous sclerosis complex, 170 (54%) had complete cessation of their infantile spasms; of the 77 patients with tuberous sclerosis complex, 73 (95%) had complete cessation of their seizures." | 6.40 | Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. ( Hancock, E; Osborne, JP, 1999) |
| "While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 5.39 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| "Although antiseizure medication is the first-line treatment for epilepsy, currently available medications are ineffective in a significant percentage of patients and have not clearly been demonstrated to have disease-specific effects for epilepsy." | 5.39 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| "Vigabatrin has been shown to be efficient in infants with infantile spasms and tuberous sclerosis, in open studies." | 5.08 | Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 1997) |
| "The purpose of this report is to review the efficacy and safety of vigabatrin in the treatment of infantile spasms in infants suffering from tuberous sclerosis complex." | 4.80 | Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. ( Hancock, E; Osborne, JP, 1999) |
| " While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 3.79 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| "The purpose of this study was to estimate the gamma-aminobutyric acid (GABA) and glutamate plus glutamine (Glx) concentrations in the cortical tubers of patients with tuberous sclerosis complex (TSC) using the MEGA-editing J-difference method and a stimulated echo-acquisition mode with a short echo time, and to determine which abnormality was more dominant between GABA and Glx in patients with TSC with epilepsy." | 3.75 | High gamma-aminobutyric acid level in cortical tubers in epileptic infants with tuberous sclerosis complex measured with the MEGA-editing J-difference method and a three-Tesla clinical MRI Instrument. ( Harada, M; Kubo, H; Matsuda, T; Mori, K; Nishitani, H; Nose, A; Taki, MM, 2009) |
| "We present the results of treatment with vigabatrin in the polytherapy of resistant infantile epilepsy." | 3.69 | [Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients]. ( Hernández-Laín, A; López-Valdés, E; Mateos, F; Porta, J; Simón, R, 1996) |
| "To study the pharmacokinetics of vigabatrin in a patient affected with tuberous sclerosis who developed major agitation and aggression, while receiving vigabatrin orally (1." | 3.69 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| "Vigabatrin has been shown to be efficient in infants with infantile spasms and tuberous sclerosis, in open studies." | 2.68 | Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 1997) |
| "Of the 313 patients without tuberous sclerosis complex, 170 (54%) had complete cessation of their infantile spasms; of the 77 patients with tuberous sclerosis complex, 73 (95%) had complete cessation of their seizures." | 2.40 | Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. ( Hancock, E; Osborne, JP, 1999) |
| "Cortical tubers in patients with tuberous sclerosis complex (TSC) are highly associated with intractable epilepsy." | 1.43 | Expression and cellular distribution of transient receptor potential vanilloid 4 in cortical tubers of the tuberous sclerosis complex. ( Chen, B; Chen, X; Li, S; Liang, C; Liu, S; Sun, F; Wang, L; Wei, Y; Yang, H; Yang, M; Yue, J, 2016) |
| "While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 1.39 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| "Although antiseizure medication is the first-line treatment for epilepsy, currently available medications are ineffective in a significant percentage of patients and have not clearly been demonstrated to have disease-specific effects for epilepsy." | 1.39 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| "Vigabatrin is an irreversible inhibitor of GABA-transaminase, effective in the treatment of drug-resistant epilepsy and reported to be eliminated unchanged by renal excretion." | 1.30 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| " A pharmacokinetic study of the S(+) and R(-) enantiomers of vigabatrin was performed before and during dialysis." | 1.30 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| " Although vigabatrin is known to have stereoselective kinetics, the difference in plasma dry concentrations and pharmacokinetics of the S(+) and R(-) enantiomers that we observed during long term administration at high doses in a patient with impaired renal function, has not been reported before." | 1.30 | Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ( Chiron, C; Guillonneau, M; Jacqz-Aigrain, E; Loirat, C; Macher, MA; Montes, C; Rey, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, B | 1 |
| McDaniel, SS | 1 |
| Rensing, NR | 1 |
| Wong, M | 1 |
| Chen, X | 1 |
| Yang, M | 1 |
| Sun, F | 1 |
| Liang, C | 1 |
| Wei, Y | 1 |
| Wang, L | 1 |
| Yue, J | 1 |
| Chen, B | 1 |
| Li, S | 1 |
| Liu, S | 1 |
| Yang, H | 1 |
| Taki, MM | 1 |
| Harada, M | 2 |
| Mori, K | 2 |
| Kubo, H | 1 |
| Nose, A | 1 |
| Matsuda, T | 1 |
| Nishitani, H | 1 |
| Mori, T | 1 |
| Toda, Y | 1 |
| Fujii, E | 1 |
| Miyazaki, M | 1 |
| Kagami, S | 1 |
| Valencia, I | 1 |
| Legido, A | 1 |
| Yelin, K | 1 |
| Khurana, D | 1 |
| Kothare, SV | 1 |
| Katsetos, CD | 1 |
| Curatolo, P | 1 |
| Aicardi, J | 1 |
| Mumford, JP | 1 |
| Dumas, C | 2 |
| Wood, S | 1 |
| López-Valdés, E | 1 |
| Hernández-Laín, A | 1 |
| Simón, R | 1 |
| Porta, J | 1 |
| Mateos, F | 1 |
| Chiron, C | 2 |
| Jambaqué, I | 1 |
| Mumford, J | 1 |
| Dulac, O | 1 |
| Jacqz-Aigrain, E | 1 |
| Guillonneau, M | 1 |
| Rey, E | 1 |
| Macher, MA | 1 |
| Montes, C | 1 |
| Loirat, C | 1 |
| Hancock, E | 1 |
| Osborne, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial[NCT04302116] | 250 participants (Anticipated) | Interventional | 2020-05-18 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gamma-aminobutyric acid and Adenoma Sebaceum
| Article | Year |
|---|---|
Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Infant; Spasms, Infantile; Tuberous Sclerosis; Vig | 1999 |
2 trials available for gamma-aminobutyric acid and Adenoma Sebaceum
| Article | Year |
|---|---|
Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups.
Topics: Age of Onset; Anticonvulsants; Child, Preschool; Dose-Response Relationship, Drug; Drug Administrati | 1996 |
Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis.
Topics: Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Hydrocortisone; Infant; Infant, Newborn; M | 1997 |
9 other studies available for gamma-aminobutyric acid and Adenoma Sebaceum
| Article | Year |
|---|---|
Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Topics: Animals; Anticonvulsants; Astrocytes; Brain; Cell Proliferation; Cells, Cultured; Disease Models, An | 2013 |
Expression and cellular distribution of transient receptor potential vanilloid 4 in cortical tubers of the tuberous sclerosis complex.
Topics: Cerebral Cortex; Child; Child, Preschool; Cyclic AMP-Dependent Protein Kinases; Female; gamma-Aminob | 2016 |
High gamma-aminobutyric acid level in cortical tubers in epileptic infants with tuberous sclerosis complex measured with the MEGA-editing J-difference method and a three-Tesla clinical MRI Instrument.
Topics: Biomarkers; Cerebral Cortex; Child; Child, Preschool; Epilepsy; Female; gamma-Aminobutyric Acid; Hum | 2009 |
Decreased benzodiazepine receptor and increased GABA level in cortical tubers in tuberous sclerosis complex.
Topics: Aspartic Acid; Brain; Case-Control Studies; Child; Child, Preschool; Female; Flumazenil; gamma-Amino | 2012 |
Anomalous inhibitory circuits in cortical tubers of human tuberous sclerosis complex associated with refractory epilepsy: aberrant expression of parvalbumin and calbindin-D28k in dysplastic cortex.
Topics: Adolescent; Adult; Biomarkers; Calbindin 1; Calbindins; Calcium; Calcium-Binding Proteins; Cerebral | 2006 |
Vigabatrin for refractory partial seizures in children with tuberous sclerosis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; gamma-Aminobutyric Acid; Humans; Infant; Retro | 1994 |
[Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients].
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Epilepsy; Female; gamma-Aminobutyric Ac | 1996 |
Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure.
Topics: Adult; Anticonvulsants; Enzyme Inhibitors; gamma-Aminobutyric Acid; Humans; Kidney Failure, Chronic; | 1997 |
Vigabatrin: new indication. An advance in infantile spasms.
Topics: Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Drug Evaluation; France; gamma-A | 1998 |